Diebold Nixdorf (DBD) Tops Q4 EPS by 130c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts DBD Hot Sheet
Price: $68.67 +0.70%
Financial Fact:
Selling and administrative expense: 127.3M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Selling and administrative expense: 127.3M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Diebold Nixdorf (NYSE: DBD) reported Q4 EPS of $3.02, $1.30 better than the analyst estimate of $1.72. Revenue for the quarter came in at $1.1 billion.
GUIDANCE:
Diebold Nixdorf sees FY2026 EPS of $5.25-$5.75, versus the consensus of $5.02. Diebold Nixdorf sees FY2026 revenue of $3.86-3.94 billion, versus the consensus of $3.9 billion.
For earnings history and earnings-related data on Diebold Nixdorf (DBD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
- HII targets 15% shipbuilding throughput increase for U.S. Navy in 2026
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
